Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. [electronic resource]
Producer: 20110308Description: 1308-16 p. digitalISSN:- 1592-8721
- Aged
- Aged, 80 and over
- Apoptosis -- drug effects
- Benzoates -- pharmacology
- Blotting, Western
- Deferasirox
- Electrophoretic Mobility Shift Assay
- Female
- Flow Cytometry
- Fluorescent Antibody Technique
- Humans
- Iron -- antagonists & inhibitors
- Iron Chelating Agents -- pharmacology
- K562 Cells
- Leukemia -- metabolism
- Male
- Middle Aged
- Myelodysplastic Syndromes -- metabolism
- NF-kappa B -- antagonists & inhibitors
- Protein Binding -- drug effects
- Reactive Oxygen Species -- antagonists & inhibitors
- Triazoles -- pharmacology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.